The U.S.-based company Micromet announced in Berlin Monday a successful clinical study of a drug designed to treat leukemia. The Micromet cancer treatment showed success in 13 of 16 patients in its level-2 clinical study. The announcement pushed company shares from $1.05 to averaging more than $6.00 per share during Monday trading as of the time of this article. The Micromet cancer treatment could be a major breakthrough for the treatment of leukemia patients in remission.
The U.S.-based company Micromet announced in Berlin Monday a successful clinical study of a drug designed to treat leukemia. The Micromet cancer treatment showed success in 13 of 16 patients in its level-2 clinical study. The announcement pushed company shares from $1.05 to averaging more than $6.00 per share during Monday trading as of the time of this article. The Micromet cancer treatment could be a major breakthrough for the treatment of leukemia patients in remission.
Source:?
Kyle Godfrey
(full text retrieval failed)Promising MicroMet Cancer Treatment Pushes Stock Higher
View this post on my blog: http://diseasecancer.net/promising-micromet-cancer-treatment-pushes-stock-higher
0 comments:
Post a Comment